Regulus Therapeutics Inc.
RGLS
Rang in aandelen
#17335
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aandeelprijs
$8.16
Laatst gesynchroniseerd: 2025-06-26
Marktkapitalisatie
$234.57M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-56.96%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Categorie
Healthcare
Omzet van Regulus Therapeutics Inc. (RGLS)
Omzet in Mar 2024 TTM: $219.60M
Volgens de laatste financiële rapporten van Regulus Therapeutics Inc. bedraagt de huidige omzet van het bedrijf (TTM) $219.60M. In 2022 behaalde het bedrijf een omzet van $298.49M een stijging ten opzichte van de omzet in het jaar 2021, die $204.23M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Regulus Therapeutics Inc. van 2002 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $219.60M | -16.63% |
| 2023 | $263.41M | -11.75% |
| 2022 | $298.49M | 46.15% |
| 2021 | $204.23M | -48.83% |
| 2020 | $399.10M | 395.72% |
| 2019 | $80.51M | -8.35% |
| 2018 | $87.84M | 9.61% |
| 2017 | $80.14M | 53.12% |
| 2016 | $52.34M | -54.62% |
| 2015 | $115.34M | 49.00% |
| 2014 | $77.41M | -27.79% |
| 2013 | $107.21M | 56.55% |
| 2012 | $68.48M | -47.51% |
| 2011 | $130.46M | 12.11% |
| 2010 | $116.37M | 0.16% |
| 2009 | $116.18M | 16.36% |
| 2008 | $99.85M | 10.24% |
| 2007 | $90.57M | 29.80% |
| 2006 | $69.78M | 640.17% |
| 2005 | $9.43M | -68.37% |
| 2004 | $29.80M | 54.60% |
| 2003 | $19.28M | 9.63% |
| 2002 | $17.58M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 5,648.72% |
US
|
|
| $2.23B | 914.56% |
US
|
|
| $15.74B | 7,069.48% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,641.91% |
NL
|
